|
UCB's Keppra Gets FDA Nod – Analyst Blog
NASDAQ Further, the company has filed for the approval of Neupro in Japan for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS). Cimzia is currently marketed in the US and EU for the treatment of adults with moderate-to-severely … |
View full post on restless leg syndrome – Google News
